Over the last several decades as the size, complexity, length, cost and globalization of clinical trials has continued to grow, the importance of contract research organizations (CROs) to the pharmaceutical industry has increased significantly. Outsourcing has become a popular way for pharmaceutical companies to utilize on-demand services to improve operational efficiency and therapeutic expertise, cut costs, and add more extensive geographic capabilities.
Technology investments are catalyzing the study startup process - an entrenched bottleneck in study conduct - with more investment coming in from CROs.
More than just a fad, this trend is nothing less than a paradigm shift in the pharmaceutical industry that has struggled to contain costs and timelines associated with trials as the rescue study services industry has boomed. But are CROs more efficient at study startup?